Trailing-twelve-month (TTM) revenue is $4.32 Billion with a year-over-year growth of (29.80%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-26 | $1,027,099,999 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $1,122,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-04-03 | $1,069,400,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-07-03 | $1,096,800,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $4,315,799,999 |
Current P/S: $16,861,612,013 market capitalization ÷ $4,315,799,999 TTM revenue = 3.91x.
Market capitalization source: FMP quote. Quote observed 2026-09-09T20:00:00.000Z. Latest revenue period ended 2026-07-03.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-07-03): $1.10B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-09T20:00:00.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Advanced Healthcare Solutions | $1.1B | $1.2B | $1.3B | $1.3B | $1.3B | $1.3B |
| Intelligent Operating Solutions | $1.9B | $2.2B | $2.5B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|---|---|---|---|
| CHINA | $592M | $534M | $651M | $702M | $695M | $648M |
| Countries Excluding United States and China | $2.5B | $1.7B | $1.9B |
$4.32B
$4.32 Billion
(29.80%)
vs. $6.15B a year ago (TTM)
+2.10%
5 Year compound annual growth rate
1 Year
(29.80%)
3 Year
(10.24%)
5 Year
+2.10%
10 Year
(3.42%)
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.14B | ($1.09B) | (17.48%) |
| 2024 | $6.23B | +$166.50M | +2.75% |
| 2023 | $6.07B | +$239.60M | +4.11% |
| 2022 | $5.83B | +$571.00M | +10.87% |
| 2021 | $5.25B | +$620.30M | +13.38% |
| 2020 |
TTM Growth
(29.80%)
3-Year CAGR
(10.24%)
5-Year CAGR
(3.14%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-09T20:00:00.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2.7B |
| $2.9B |
| Precision Technologies | $1.7B | $1.8B | $2.0B | $2.1B | $2.2B | N/A |
|---|
| $2.1B |
| $2.2B |
| UNITED STATES | $4.2B | $2.4B | $2.7B | $3.1B | $3.3B | $3.4B |
|---|
| $4.63B |
| +$70.50M |
| +1.54% |
| 2019 | $4.56B | ($1.89B) | (29.27%) |
| 2018 | $6.45B | +$696.60M | +12.10% |
| 2017 | $5.76B | ($468.20M) | (7.52%) |
| 2016 | $6.22B | +$45.50M | +0.74% |
